niacinamide has been researched along with 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blay, JY; Dumont, AG; Dumont, SN; Reynoso, D; Trent, JC; Yang, D | 1 |
| Bobb, D; Dome, JS; He, J; Hill, DA; Hu, Y | 1 |
2 other study(ies) available for niacinamide and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
| Article | Year |
|---|---|
Targeted polytherapy in small cell sarcoma and its association with doxorubicin.
Topics: Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Doxorubicin; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Sarcoma, Small Cell; Sorafenib; Vorinostat | 2014 |
The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA Damage; Enzyme Activation; Enzyme Inhibitors; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Mice; Niacinamide; Oligonucleotides; Osteosarcoma; Signal Transduction; Telomerase; Telomere Shortening; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |